POLYNOVO LIMITED (PNV)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

PNV - POLYNOVO LIMITED

Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Index: ASX200 | ASX300 | ALL-ORDS

PolyNovo is an Australian medical devices company developing and commercialising its NovoSorb technology for the treatment of burns, wounds and negative pressure wound therapy. It has been a listed company since 1998.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$1.87

21 Oct
2021

0.000

OPEN

$1.90

0.000

HIGH

$1.94

2,403,762

LOW

$1.87

TARGET
$2.55 36.4% upside
OTHER COMPANIES IN THE SAME SECTOR
CUV . ACR . AHZ . CSL . IDT . IVX . MSB . MYX . RNO . OSL . TFC . TIS . KZA . AGH . FTT . PAR . ADO . PYC . RAC . RCE . ZNO . AVH . LGP . SPL . ARX . AFP . 1AD . TLX . MVP . BNO . NXS . GSS . EOF . NEU . PAL . PBP . BOT . IMU . MDC . IMM . PXS . OPT . ANP .
FNARENA'S MARKET CONSENSUS FORECASTS
PNV: 1
Title FY20
Actual
FY21
Actual
FY22
Forecast
FY23
Forecast
EPS (cps) xxx - 0.7 0.1 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A 3700.0 xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A 0.0% xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

0.00

Estimated Dividend Growth
(Average Of Past Three Years)

 %

Amount Invested

Tell Me The Dividend After This Many Years

Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2021 FactSet UK Limited. All rights reserved
Title 201620172018201920202021
EPS Basic xxxxxxxxxxxxxxx-0.7
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx29.2 M
Book Value Per Share xxxxxxxxxxxxxxx3.4
Net Operating Cash Flow xxxxxxxxxxxxxxx-0.2 M
Net Profit Margin xxxxxxxxxxxxxxx-15.79 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201620172018201920202021
Return on Capital Employed xxxxxxxxxxxxxxx-19.95 %
Return on Invested Capital xxxxxxxxxxxxxxx-15.96 %
Return on Assets xxxxxxxxxxxxxxx-12.09 %
Return on Equity xxxxxxxxxxxxxxx-19.95 %
Return on Total Capital xxxxxxxxxxxxxxx-9.51 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-3.8 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

This is work in progress. Bear with us. It'll be amazing.

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.5

No. Of Recommendations

2
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Macquarie

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

24/09/2021

3

Hold

$2.25

20.32%

Regarding Syntrel, Polynovo’s long acting resorbable hernia mesh, a 24-month delay could result in greater adoption hurdles and greater competition post approval, explains Ord Minnett. The target falls to $2.25 from $2.54 upon a reduced hernia valuation.

The broker doesn't see meaningful revenues until FY26 and assumes a more competitive market dynamic. Despite this, the limitations of biologics and permanent synthetics are considered to increase the overall market for the resorbable synthetic and hybrid category.

FORECAST
Ord Minnett forecasts a full year FY22 dividend of 0.00 cents and EPS of 0.00 cents.
Ord Minnett forecasts a full year FY23 dividend of 0.00 cents and EPS of 1.90 cents.

PNV STOCK CHART